660-661 / 1726
•
Stage I-II HIR factors
•
Stage I-II serous / cc
R
Pelvic RT
3x carboplatin
+ paclitaxel + VBT
Completed accrual 2012
N=601, primary endpoint PFS
89% underwent lymphadenectomy
15% serous, 5% clear cell, 74% stage I
First GOG#249 results
McMeekin, SGO 2014, Fleming, IGCS 2014; Randall ASTRO 2017
Update, median FU 53 months
No difference RFS and Overall Survival